Wells Fargo’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-79,557
| Closed | -$4.19M | – | 7593 |
|
|
2026
Q1 | $4.19M | Sell |
79,557
-16,751
| -17% | -$688K | ﹤0.01% | 2741 |
|
|
2025
Q4 | $3.89M | Buy |
96,308
+40,716
| +73% | +$941K | ﹤0.01% | 2911 |
|
|
2025
Q3 | $417K | Buy |
55,592
+9,041
| +19% | +$57.7K | ﹤0.01% | 4428 |
|
|
2025
Q2 | $174K | Buy |
46,551
+4,662
| +11% | +$14.6K | ﹤0.01% | 4852 |
|
|
2025
Q1 | $116K | Buy |
41,889
+923
| +2% | +$3.77K | ﹤0.01% | 5034 |
|
|
2024
Q4 | $227K | Buy |
40,966
+14,846
| +57% | +$101K | ﹤0.01% | 4725 |
|
|
2024
Q3 | $218K | Buy |
26,120
+1,039
| +4% | +$8.55K | ﹤0.01% | 4512 |
|
|
2024
Q2 | $171K | Buy |
25,081
+11,024
| +78% | +$66.8K | ﹤0.01% | 4620 |
|
|
2024
Q1 | $92.2K | Buy |
14,057
+2,003
| +17% | +$13.1K | ﹤0.01% | 4940 |
|
|
2023
Q4 | $78.2K | Buy |
12,054
+2,568
| +27% | +$13.6K | ﹤0.01% | 5052 |
|
|
2023
Q3 | $47.7K | Sell |
9,486
-7,827
| -45% | -$49.7K | ﹤0.01% | 5203 |
|
|
2023
Q2 | $151K | Buy |
17,313
+17,104
| +8,184% | +$199K | ﹤0.01% | 4761 |
|
|
2023
Q1 | $2.48K | Buy |
209
+83
| +66% | +$793 | ﹤0.01% | 6193 |
|
|
2022
Q4 | $1.28K | Buy |
126
+4
| +3% | +$27 | ﹤0.01% | 6112 |
|
|
2022
Q3 | $1K | Buy |
122
+70
| +135% | +$260 | ﹤0.01% | 6472 |
|
|
2022
Q2 | $0 | Sell |
52
-561
| -92% | -$1.12K | ﹤0.01% | 7478 |
|
|
2022
Q1 | $2K | Sell |
613
-4,866
| -89% | -$20.8K | ﹤0.01% | 6703 |
|
|
2021
Q4 | $39K | Buy |
5,479
+5,464
| +36,427% | +$45.5K | ﹤0.01% | 6084 |
|
|
2021
Q3 | $0 | Buy |
+15
| New | +$156 | ﹤0.01% | 7512 |
|
|
2021
Q2 | – | Sell |
-2,714
| Closed | -$60K | – | 7430 |
|
|
2021
Q1 | $60K | Buy |
+2,714
| New | +$59.5K | ﹤0.01% | 5735 |
|
Other funds holding TERN
Wells Fargo's TERN Position: Q2 2026 in Review
Wells Fargo sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 79,557 shares — an estimated $4.19M sold.
Wells Fargo first reported a position in TERN in Q1 2021 and held it in 20 quarters. The position peaked at $4.19M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Wells Fargo reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Wells Fargo sold 79,557 Terns Pharmaceuticals shares in Q2 2026, an estimated $4.19M.
- Wells Fargo first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 20 quarters.
- Wells Fargo's Terns Pharmaceuticals position peaked at $4.19M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.